Review of the Endocannabinoid System
Hui-Chen Lu, Ken Mackie
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging August 1, 2020 DOI: 10.1016/j.bpsc.2020.07.016 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The review summarizes current understanding of the endocannabinoid system, describing its components, their roles in synaptic plasticity and neurodevelopment, and how cannabinoid receptors serve as the primary target of THC. It further discusses how phytocannabinoids and other exogenous compounds may perturb the ECS, emphasizing examples relevant to psychosis. |
Abstract
The endocannabinoid system (ECS) is a widespread neuromodulatory network involved both in the developing CNS as well as playing a major role in tuning many cognitive and physiological processes. The ECS is composed of endogenous cannabinoids, cannabinoid receptors and the enzymes responsible for the synthesis and degradation of endocannabinoids. In addition to its endogenous roles, cannabinoid receptors are the primary target of Δ9-tetrahydrocannabinol (THC), the intoxicating component of cannabis. In this review, we will summarize our current understanding of the ECS. We will start with a description of ECS components and their role in synaptic plasticity and neurodevelopment, and then discuss how phytocannabinoids and other exogenous compounds may perturb the ECS, emphasizing examples relevant to psychosis.
Citations in the library
Cited by 24
- Gender Differences in Dual Diagnoses Associated with Cannabis Use: A Review Brain Sciences March 15, 2022
- Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats Progress in Neuro-Psychopharmacology and Biological Psychiatry 2025
- The Relationship Between Cannabis, Cognition, and Schizophrenia: It’s Complicated Current Topics in Behavioral Neurosciences 2022
- Treatment Approaches for Posttraumatic Stress Disorder Derived From Basic Research on Fear Extinction. Biological Psychiatry February 15, 2025
- Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats. Neuropsychopharmacology December 1, 2024
and 19 more in the library
Cites 9
- Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone Nature Neuroscience September 11, 2019
- The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study The Lancet Psychiatry May 1, 2019
- Psychosis and synthetic cannabinoids. Psychiatry Research October 2018
- Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacology January 2018
- Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology July 2016
and 4 more in the library